Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | APP | P05067 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.46 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6680832 | 0.89 | HPGD (0.51) | HPGDLMNAAPPSMN1; SMN2KDM4E | |
| SCHEMBL7910931 | 0.87 | HTT (0.53) | LMNAMAOBAPPSMN1; SMN2RAB9A | |
| SCHEMBL3744492 | 0.86 | FFAR4 (0.46) | FFAR4HPGDSMN1; SMN2KDM4ENPC1 | |
| SCHEMBL16624239 | 0.86 | MAOB (0.61) | MAOBAPPSMN1; SMN2MCL1MAPT | |
| SCHEMBL3962253 | 0.86 | MAOB (0.61) | FFAR4HPGDLMNAMAOBSMN1; SMN2 | |
| SCHEMBL1316057 | 0.85 | MCL1 (0.56) | MAOBAPPSMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL11557673 | 0.84 | KDM4E (0.60) | FFAR4HPGDLMNAMAOBAPP | |
| SCHEMBL27696681 | 0.84 | MAOB (0.44) | HPGDLMNAMAOBAPPSMN1; SMN2 | |
| SCHEMBL14891403 | 0.83 | FFAR4 (0.54) | FFAR4HPGDLMNAALDH1A1SMPD1 | |
| SCHEMBL21434703 | 0.83 | PTGER1 (0.57) | FFAR4HPGDLMNASMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11426714-B2 | Metal organic frameworks (MOFs) and methods of synthesizing and using the same | VIETNAM NATIONAL UNIVERSITY HO CHI MINH CITY (VN) | 2022-08-30 | — | — | US | disclosed |
| US-20210162388-A1 | METAL ORGANIC FRAMEWORKS (MOFs) AND METHODS OF SYNTHESIZING AND USING THE SAME | Center for Innovative Materials and Architectures (VN) | 2021-06-03 | — | — | US | disclosed |
| US-10875844-B2 | Salicylate inhibitors of MELK and methods of use | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-12-29 | — | — | US | disclosed |
| US-10875844-B2 | Salicylate inhibitors of MELK and methods of use | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-12-29 | — | — | US | disclosed |
| CN-104302387-B | Metal organic framework with exceptionally large pore openings | 加利福尼亚大学董事会 | 2019-06-18 | — | — | CN | disclosed |
| EP-3063139-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2018-11-21 | — | — | EP | disclosed |
| US-20180170912-A1 | SALICYLATE INHIBITORS OF MELK AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. | 2018-06-21 | — | — | US | disclosed |
| US-20180170912-A1 | SALICYLATE INHIBITORS OF MELK AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. | 2018-06-21 | — | — | US | disclosed |
| US-20180170912-A1 | SALICYLATE INHIBITORS OF MELK AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. | 2018-06-21 | — | — | US | disclosed |
| EP-3055309-B1 | ANTAGONISTS OF SOMATOSTATIN RECEPTOR SUBTYPE 5 (SSTR5) | TAKEDA PHARMACEUTICALS CO (JP) | 2018-06-13 | — | — | EP | disclosed |
| US-20110275797-A1 | N-ACYL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2011-11-10 | — | — | US | disclosed |
| EP-2385036-A1 | N-ACYL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | Toyama Chemical Co., Ltd. (JP) | 2011-11-09 | — | — | EP | disclosed |
| US-7829588-B2 | Modulators of the PPAR-type receptors and pharmaceutical/cosmetic applications thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-11-09 | — | — | US | disclosed |
| EP-2222648-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ASTHMA, COPD, ALLERGIC RHINITIS, ALLERGIC CONJUNCTIVITIS, ATOPIC DERMATITIS, CANCER, HEPATITIS B, HEPATITIS C, HIV, HPV, BACTERIAL INFECTIONS AND DERMATOSIS | AstraZeneca AB (SE) | 2010-09-01 | — | — | EP | disclosed |
| US-20090209524-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2009-08-20 | — | — | US | disclosed |
| WO-2009067081-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ASTHMA, COPD, ALLERGIC RHINITIS, ALLERGIC CONJUNCTIVITIS, ATOPIC DERMATITIS, CANCER, HEPATITIS B, HEPATITIS C, HIV, HPV, BACTERIAL INFECTIONS AND DERMATOSIS | ASTRAZENECA AB (SE) | 2009-05-28 | — | — | WO | disclosed |
| EP-1694669-B1 | NOVEL COMPOUNDS WHICH ARE MODULATORS OF THE PPAR-TYPE RECEPTORS AND THEIR USE IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | GALDERMA RES & DEV (FR) | 2007-04-11 | — | — | EP | disclosed |
| US-20070054907-A1 | Peroxisome Proliferator-Activated Receptor (PPAR) receptor modulators such as Ethyl(4-{4-[5-(4-tert-butylphenyl)-4-methyl-4H-[1,2,4]-triazol-3-ylsulfanyl]-2-heptyloxybenzylamino}phenyl)acetate, used in dermatology, cardiovascular diseases, immunology and/or diseases linked to lipid metabolism | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2007-03-08 | — | — | US | disclosed |
| EP-1694669-A2 | NOVEL COMPOUNDS WHICH ARE MODULATORS OF THE PPAR-TYPE RECEPTORS AND THEIR USE IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | Galderma Research & Development, S.N.C. (FR) | 2006-08-30 | — | — | EP | disclosed |
| WO-2005058844-A2 | NOVEL COMPOUNDS WHICH ARE MODULATORS OF THE PPAR-TYPE RECEPTORS AND THEIR USE IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2005-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180170912-A1 | SALICYLATE INHIBITORS OF MELK AND METHODS OF USE | MELK, HIPK3, MINK1 | FFAR4 4573/4885HPGD 4010/4885LMNA 1670/4885 |
| US-20070054907-A1 | Peroxisome Proliferator-Activated Receptor (PPAR) receptor modulators such as Ethyl(4-{4-[5-(4-tert-butylphenyl)-4-methyl-4H-[1,2,4]-triazol-3-ylsulfanyl]-2-heptyloxybenzylamino}phenyl)acetate, used in dermatology, cardiovascular diseases, immunology and/or diseases linked to lipid metabolism | PPARG, PPARA, PPARD | FFAR4 5/4885HPGD 663/4885LMNA 3741/4885 |
| US-20110275797-A1 | N-ACYL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | COL14A1, COL2A1, COL1A1 | FFAR4 2368/4885HPGD 1236/4885LMNA 546/4885 |
| US-20090209524-A1 | Novel Compounds | ABCG2, CYP4B1, CYP3A4 | FFAR4 645/4885HPGD 3366/4885LMNA 4207/4885 |
| US-10875844-B2 | Salicylate inhibitors of MELK and methods of use | MELK, HIPK3, MINK1 | FFAR4 4573/4885HPGD 4010/4885LMNA 1670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.